Home >> Research Area >>Metabolism>>DGAT>> ABT-046

ABT-046

DGAT-1 inhibitor,potent and selective CAS# 1031336-60-3

ABT-046

Catalog No. BCC1326----Order now to get a substantial discount!

Product Name & Size Price Stock
ABT-046: 5mg $276 In Stock
ABT-046: 10mg Please Inquire In Stock
ABT-046: 20mg Please Inquire Please Inquire
ABT-046: 50mg Please Inquire Please Inquire
ABT-046: 100mg Please Inquire Please Inquire
ABT-046: 200mg Please Inquire Please Inquire
ABT-046: 500mg Please Inquire Please Inquire
ABT-046: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of ABT-046

Number of papers citing our products

Chemical structure

ABT-046

3D structure

Chemical Properties of ABT-046

Cas No. 1031336-60-3 SDF Download SDF
PubChem ID 56933229 Appearance Powder
Formula C20H22N4O2 M.Wt 350.41
Type of Compound N/A Storage Desiccate at -20°C
Synonyms DGAT-1 inhibitor
Solubility DMSO : 66.67 mg/mL (190.26 mM; Need ultrasonic)
Chemical Name 2-[4-[4-(7-aminopyrazolo[1,5-a]pyrimidin-6-yl)phenyl]cyclohexyl]acetic acid
SMILES C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)C3=C(N4C(=CC=N4)N=C3)N
Standard InChIKey BWUXSHHOKODNAK-UHFFFAOYSA-N
Standard InChI InChI=1S/C20H22N4O2/c21-20-17(12-22-18-9-10-23-24(18)20)16-7-5-15(6-8-16)14-3-1-13(2-4-14)11-19(25)26/h5-10,12-14H,1-4,11,21H2,(H,25,26)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of ABT-046

DescriptionABT-046 is a potent, selective, and orally bioavailable Diacylglycerol acyltransferase 1 (DGAT-1 ) inhibitor (IC50= 8 nM). IC50 value: 8 nM [1] Target: DGAT-1 Oral administration at doses ≥0.03 mg/kg significantly reduced postprandial triglycerides in mice following an oral lipid challenge. Further assessment in both acute and chronic safety pharmacology and toxicology studies demonstrated a clean profile up to high plasma levels, thus culminating in the nomination of 14 as clinical candidate ABT-046.

References:
[1]. Yeh VS, et al. Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of Acyl-CoA: Diacylglycerol acyltransferase 1. J Med Chem. 2012 Feb 23;55(4):1751-1757.

ABT-046 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

ABT-046 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of ABT-046

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.8538 mL 14.269 mL 28.538 mL 57.076 mL 71.345 mL
5 mM 0.5708 mL 2.8538 mL 5.7076 mL 11.4152 mL 14.269 mL
10 mM 0.2854 mL 1.4269 mL 2.8538 mL 5.7076 mL 7.1345 mL
50 mM 0.0571 mL 0.2854 mL 0.5708 mL 1.1415 mL 1.4269 mL
100 mM 0.0285 mL 0.1427 mL 0.2854 mL 0.5708 mL 0.7134 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on ABT-046

The final and only committed step in the synthesis of triglycerides is common to both major triglyceride biosynthesis pathways and is catalyzed by acyl CoA:diacylglycerol acyltransferase (DGAT) enzymes. DGAT-1, in particular, has received significant attention as a therapeutic target for cardiometabolic diseases. A high-throughput screen against human DGAT-1 led to the identification of a core structure that was subsequently optimized to afford the potent, selective, and orally bioavailable compound ABT-046.
In vitro: ABT-046 showed potent inhibition against both human and mouse isoforms of DGAT-1 (IC50 = 8 nM) and retained much of the high BE (BE = 23.1). Additionally, this compound showed no inhibition against human DGAT-2 and inhibited triglyceride formation in HeLa cells expressing human DGAT-1 with an IC50 of 78 nM. [1].
In vivo: Oral administration of ABT-046 at doses ≥0.03 mg/kg significantly reduced postprandial triglycerides in mice following an oral lipid challenge. Further assessment in both acute and chronic safety pharmacology and toxicology studies demonstrated a clean profile up to high plasma levels.
Clinical trial: ABT-046 is currently in the preclinical developlent stage and no clinical data are available.
Reference:
[1] Yeh VS, Beno DW, Brodjian S, Brune ME, Cullen SC, Dayton BD, Dhaon MK, Falls HD, Gao J, Grihalde N, Hajduk P, Hansen TM, Judd AS, King AJ, Klix RC, Larson KJ, Lau YY, Marsh KC, Mittelstadt SW, Plata D, Rozema MJ, Segreti JA, Stoner EJ, Voorbach MJ, Wang X, Xin X, Zhao G, Collins CA, Cox BF, Reilly RM, Kym PR, Souers AJ. Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1. J Med Chem. 2012;55(4):1751-7.

Featured Products
New Products
 

References on ABT-046

Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1.[Pubmed:22263872]

J Med Chem. 2012 Feb 23;55(4):1751-7.

A high-throughput screen against human DGAT-1 led to the identification of a core structure that was subsequently optimized to afford the potent, selective, and orally bioavailable compound 14. Oral administration at doses >/=0.03 mg/kg significantly reduced postprandial triglycerides in mice following an oral lipid challenge. Further assessment in both acute and chronic safety pharmacology and toxicology studies demonstrated a clean profile up to high plasma levels, thus culminating in the nomination of 14 as clinical candidate ABT-046.

Description

ABT-046 is a potent, selective, and orally efficacious acyl CoA:diacylglycerol acyltransferase 1 (DGAT-1) inhibitor (IC50= 8 nM).

Keywords:

ABT-046,1031336-60-3,DGAT-1 inhibitor,Natural Products,DGAT, buy ABT-046 , ABT-046 supplier , purchase ABT-046 , ABT-046 cost , ABT-046 manufacturer , order ABT-046 , high purity ABT-046

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: